The CBX5 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A2780 human ovarian carcinoma cell line. This product provides a heterogeneous pool of cells harboring targeted disruptions in the CBX5 gene, enabling loss-of-function studies without clonal isolation. The polyclonal format maintains broad representation and is well-suited for pooled screens and bulk analyses.
A2780 is a cisplatin-sensitive ovarian cancer cell line from an untreated patient, widely used to study drug response and tumor biology. Its adherent epithelial morphology and stable karyotype support reproducible experiments, and its sensitivity to platinum agents makes it valuable for probing chemoresistance mechanisms. This cell line serves as a relevant platform for ovarian cancer genetics and epigenetic studies.
CBX5 encodes HP1??, a heterochromatin protein that binds H3K9me3 and mediates gene silencing and genome stability. HP1?? is recruited by H3K9 methyltransferases like SUV39H1/2 and SETDB1, and it interacts with repressive complexes including KAP1, Lamin B receptor, DNMT1, HDAC1/2, and CHAF1A to maintain heterochromatin. It regulates downstream targets such as CDKN1A, CDH1, and E2F-responsive genes, and is implicated in DNA damage repair and cellular senescence. Disruption of CBX5 derepresses these targets and perturbs heterochromatin architecture.
In the A2780 ovarian cancer context, CBX5 knockout disrupts heterochromatin, derepresses silenced loci, and may alter drug sensitivity. Because A2780 cells are cisplatin-sensitive, this model is particularly useful for investigating how HP1?? loss affects DNA damage responses and platinum cytotoxicity. Potential changes in BIRC5 (survivin) expression or senescence pathways can illuminate epigenetic contributions to chemoresistance. The polyclonal nature allows assessment of population-level effects, beneficial for drug screens.
These cells enable studies in epigenetic regulation, gene silencing, and heterochromatin biology. Assays include Western blotting, RT-qPCR, RNA-seq, ChIP-qPCR for H3K9me3 and HP1??, and immunofluorescence. Functional techniques such as flow cytometry (cell cycle, apoptosis), cisplatin sensitivity tests, senescence-associated ??-galactosidase staining, and clonogenic assays are directly applicable. The model also supports cancer drug resistance research and CRISPR-based screens. For further technical specifications or ordering information, please contact Ascent Research.
